Zura Bio (NASDAQ:ZURA - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.09, Zacks reports. The business had revenue of $0.00 million for the quarter.
Zura Bio Stock Down 6.6 %
NASDAQ:ZURA traded down $0.09 during trading hours on Friday, reaching $1.27. 218,258 shares of the company's stock were exchanged, compared to its average volume of 377,376. Zura Bio has a 1-year low of $1.07 and a 1-year high of $6.35. The firm has a market capitalization of $82.60 million, a price-to-earnings ratio of -2.39 and a beta of 0.06. The company has a 50-day moving average of $1.46 and a 200 day moving average of $2.73.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on ZURA. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zura Bio in a research report on Wednesday, December 11th. Oppenheimer reiterated an "outperform" rating and set a $19.00 target price (down previously from $20.00) on shares of Zura Bio in a research note on Wednesday. Chardan Capital cut their price target on Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday. HC Wainwright reaffirmed a "neutral" rating and set a $5.00 price objective on shares of Zura Bio in a research report on Tuesday, December 24th. Finally, Guggenheim reiterated a "buy" rating and issued a $15.00 price target on shares of Zura Bio in a research note on Wednesday. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $15.00.
Read Our Latest Report on Zura Bio
Institutional Investors Weigh In On Zura Bio
A hedge fund recently raised its stake in Zura Bio stock. Bank of America Corp DE raised its stake in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) by 31.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 41,222 shares of the company's stock after acquiring an additional 9,966 shares during the period. Bank of America Corp DE owned approximately 0.06% of Zura Bio worth $103,000 as of its most recent SEC filing. 61.14% of the stock is currently owned by institutional investors and hedge funds.
About Zura Bio
(
Get Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
See Also
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
